Skip to main content
    B

    Bio-Techne Corp (TECH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $72.79
    -0.01 (-0.01%)

    Market Cap: $11.44B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Bio-Techne Corp (TECH) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Bio-Techne (TECH) trades at 39.6x trailing earnings and 9.3x sales. Its P/E of 39.6x is above its 5-year median of 39.2x. Its forward P/E is 35.7x. The median P/E across 5 similar companies is 40.4x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 10.9% higher over the next year. Its free cash flow yield is 2.7%.

    MultipleValue
    P/E (trailing)39.6x
    Forward P/E35.7x
    Price to sales9.3x
    Price to book5.3x
    EV/EBITDA33.4x
    Price to FCF37.0x
    EV/FCF36.5x
    PEG2.2
    FCF yield2.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 1.0% below 40.0x, its P/S is 13.4% above 8.2x and its P/B is 3.6% below 5.5x.

    MultipleCurrent5-year median10-year median
    P/E39.6x39.2x40.0x
    P/S9.3x10.0x8.2x
    P/B5.3x5.6x5.5x
    Medians of month-end values through Oct 2026: 59 to 60 months (5-year) and 111 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 28.9x in 2016 to 69.9x in 2021.

    Year endPriceP/EP/SP/B
    2025$58.8130.8x7.6x4.6x
    2024$72.0339.8x9.6x5.5x
    2023$77.1640.8x10.7x6.2x
    2022$82.8842.1x11.7x7.1x
    2021$129.3469.9x19.9x11.9x
    2020$79.3957.9x15.4x8.1x
    2019$54.8847.7x4.6x1.8x
    2018$36.1831.2x2.5x1.2x
    2017$32.3932.4x4.7x4.9x
    2016$25.7128.9x4.2x1.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TECH

    What is TECH's forward P/E ratio?

    Bio-Techne has a forward P/E ratio of 35.7x.

    Is TECH stock overvalued?

    GNG's valuation label for TECH is Undervalued. Its P/E of 39.6x compares with a median of 40.4x across 5 similar companies.

    What is TECH's price to sales ratio?

    Bio-Techne has a price to sales ratio of 9.3x.

    What is Bio-Techne's average P/E ratio over 5 years?

    Bio-Techne's median P/E over the last 5 years is 39.2x, from 60 month-end values through Oct 2026.

    What is TECH's PEG ratio?

    Bio-Techne has a PEG ratio of 2.2.